Respiratory medication use in Australia 2003–2013: treatment of asthma and COPD

Publication
Release Date: 05 May 2015
Author: AIHW
Media release

PDF Report (1.4Mb)

Enter the email address where you would like the PDF sent. This address will not be used for any other purpose.

This report describes patterns of dispensing of respiratory medications in Australia through detailed analyses of Pharmaceutical Benefits Scheme (PBS) data, as well as other sources, to draw inferences about respiratory medication use among patients with asthma and COPD. It provides a valuable update and new information about the use of medicines for asthma and COPD, thus improving our knowledge and understanding about how these diseases are managed in Australia.

ISBN: 978-1-74249-715-0
Cat. no: ACM 31
Pages: 85

Preliminary material
- Title and verso page
- Contents
- Acknowledgments
- Abbreviations
- Summary
Body section
- 1 Introduction
  - Rationale for this report
  - Classes of medications
  - Management guidelines for asthma
  - Management guidelines for COPD
  - Context of this report
  - Questions considered in this report
- 2 Data and methods
  - Data sources
  - Methods of data analyses
- 3 Use of medications for obstructive airway disease
  - Overall medication use
  - Use of SABA for asthma (NSW Health Survey)
  - Corticosteroids
  - Long-acting bronchodilators (LABA and LAMA) prescribed without ICS
  - Anti-immunoglobulin E therapy (omalizumab)
  - Leukotriene receptor antagonists
  - Use of asthma medication in children (LSAC data)
- 4 Discussion and implications
End matter
- Appendix 1: PBS items included in the analyses for this report
- Appendix 2: PBS data processing
- Appendix 3: Inhaled corticosteroid potency classification
- Glossary
- References
- List of tables
- List of figures
- Related publications

Find reports & data by topic

Featured reports

Featured

Respiratory medication use in Australia 2003–2013: treatment of asthma and COPD

Table of contents

AIHW

Feedback